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Abstract
Human bocavirus (HBoV) is a parvovirus recently identified in association with acute respiratory infections (ARI). Despite its
worldwide occurrence, little is known on the pathogenesis of HBoV infections. In addition, few systematic studies of HBoV in
ARI have been conducted in Latin America. Therefore, in order to test whether active viral replication of human bocavirus is
associated with respiratory diseases and to understand the clinical impact of this virus in patients with these diseases, we
performed a 3-year retrospective hospital-based study of HBoV in outpatients and inpatients with symptoms of Acute
Respiratory Infections (ARI) in Brazil. Nasopharyngeal aspirates (NPAs) from 1015 patients with respiratory symptoms were
tested for HBoV DNA by PCR. All samples positive for HBoV were tested by PCR for all other respiratory viruses, had HBoV
viral loads determined by quantitative real time PCR and, when possible, were tested by RT-PCR for HBoV VP1 mRNA, as
evidence of active viral replication. HBoV was detected in 4.8% of patients, with annual rates of 10.0%, 3.0% and 3.0% in
2005, 2006 and 2007, respectively. The range of respiratory symptoms was similar between HBoV-positive and HBoV-
negative ARI patients. However, a higher rate of diarrhea was observed in HBoV-positive patients. High HBoV viral loads
(.10
8 copies/mL) and diarrhea were significantly more frequent in patients with exclusive infection by HBoV and in patients
with detection of HBoV VP1 mRNA than in patients with viral co-infection, detected in 72.9% of patients with HBoV. In
summary, our data demonstrated that active HBoV replication was detected in a small percentage of patients with ARI and
was correlated with concurrent diarrhea and lack of other viral co-infections.
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Introduction
The discovery of human bocavirus (HBoV) was the result of a
viral metagenomic study of respiratory secretions from Swedish
children with symptoms of acute respiratory infection (ARI)
reported in 2005 [1]. HBoV is classified in the family Parvoviridae,
which includes small non-enveloped, icosahedral viruses with
5.3 kb single-stranded DNA genome containing three open
reading frames (ORFs). The first two sequential ORFs encode
non-structural proteins NS1 and NP-1, whereas the third
downstream ORF encodes two viral capsid proteins, VP1 and
VP2 [1]. HBoV circulates worldwide [2] and more recent
phylogenetic analyses revealed that three novel HBoV species,
different from the respiratory HBoV1, named HBoV2, 3 and 4,
are frequently detected in stools from children with acute
gastroenteritis [3,4,5,6].
HBoV is often detected in patients with ARI [7,8,9], including
those with wheezing, croup, cough, rhinorrhea and fever [2,10].
The most frequent clinical diagnoses associated with respiratory
HBoV are general upper respiratory tract infections (URTI),
bronchiolitis, pneumonia, bronchitis and exacerbation of asthma
[2]. Symptoms associated with HBoV usually last 1–2 weeks
[11,12], but the agent has also been detected in association with
prolonged fever [13]. An association of HBoV with respiratory
disease has been based mostly on the significantly higher
frequencies of detection of the agent in ARI patients than in
control subjects without respiratory symptoms [8,10,14]. HBoV is
also detected in feces from children with diarrhea with frequencies
ranging from 0.8% to 9% [6,15,16]. In addition, HBoV DNA has
been detected in tonsil tissue in children with chronic tonsillitis
undergoing surgical resection [17,18].
Although HBoV has been propagated in primary cultures of
human respiratory cells [19], isolation of the agent from clinical
samples has not been achieved in common cell lines. Moreover, no
experimental animal model of HBoV infection has been
developed, which hampers fulfillment of Koch’s postulates for a
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further complicated by the possibility that HBoV may persist in a
way similar to other viruses of the family Parvoviridae [20], with
consequent prolonged detection in human secretions. In addition,
detection of HBoV DNA by PCR is commonly associated with
detection of genomes of other viruses whose roles in pathogenesis
of human diseases is already established [21].
This article reports a cross-sectional study of HBoV in ARI
patients from Ribeira ˜o Preto, Brazil, in which the shedding of VP1
mRNA in respiratory secretions was used as surrogate marker for
active HBoV replication, to look for correlations with viral load,
and presence of particular clinical manifestations and simulta-
neous detection of other respiratory viruses.
Results
Frequency and over time distribution of HBoV detection
HBoV genome was detected by PCR in 48 out of 1015 (4.8%)
respiratorysamplesfromARIpatients.Outofthe48HBoVpositive
samples, 40 (83.3%) were from patients under or equal to 2 years of
age (#2 years old) and only 2 (4.1%) were from adult patients.
HBoV was detected in 2.8% of 70 adult patients enrolled in the
study. The patient demographics and clinical information are
summarized on Table 1. The vast majority of studied patients were
under or equal to 2 years of age, in annual proportions of 93.3%
(239/256) in 2005, 69.2% (234/338) in 2006, and 59.8% (252/421)
in 2007. The overall frequency of HBoV detection was 10.0% in
2005 and 3.0% both in 2006 and 2007, with monthly rates that did
not indicate consistent seasonality (Figure 1). It was noticeable that
HBoV circulated roughly along with HRSV (Figure 1). In this 3-
year study period, there was a trend for an increase in the total
number of respiratory samples from children submitted for viral
testing, HRSV and HBoV positivity, in association with dry season
and declining average montly temperatures [22].
It is noteworthy that HBoV was not detected in stored samples
obtained from 50 patients without respiratory symptoms, seen at
the emergency room for reasons unrelated to the respiratory tract
from 1999 to 2000 [23].
Clinical analyses
For the purpose of the analysis, the patients were divided into
two groups: those with age equal or less than 2 years of age (410
males and 335 females; median and mean age 6 SD: 5 and
6.4565.49 months), and those older than 2 years (125 males and
145 females; 63.5 and 145.156187.75 months). In general, the
clinical findings were more severe in patients younger than 2 years
(Table S2). The most frequent respiratory symptoms/signs
(present in .50%) seen in HBoV-positive patients were cough,
fever, dyspnea and coryza, but wheezing, nasal obstruction and
sneezing were also recorded. No significant differences were noted
in the frequencies of specific respiratory symptoms/signs between
HBoV positive and negative patients (Table 1).
Of 1015 studied patients, 721 (71.0%) were diagnosed with
LRTI and 294 (28.9%) with URTI. The complications of AOM
and GERD were diagnosed in 77 (7.6%) and 44 (4.4%) patients,
respectively (Table S2). Over one third of the patients had illness
of low or moderate severity and 37.0% of them had an ICS=0 or
1,and only 5.7% had ICS=6 or 7 (Table 1).
Significantly higher frequencies of LRTI (85.4% vs. 72.2%,
p=0.01), requirement for hospitalization (83.3% vs. 67.5%,
p=0.02), and diarrhea (20.8% vs. 5.5%, p,0.01) were noted in
the 48 HBoV-positive patients, in comparison with the 967
HBoV-negative ones (p,0.05) (Table 1). No significant association
was noted between HBoV positivity and the presence of specific
signs or symptoms (Table 1). Also, no significant differences were
noted in length of hospital stay, rates of requirements for O2 and
positive airway pressure, AOM, and illness severity as measured by
ICS, between HBoV positive and negative patients (Table 1).
While the frequency of GERD was roughly twice as high in
HBoV-positive, than in HBoV-negative patients (p=0.04), only 4
HBoV patients had GERD (Table 1), a low number of cases that
restricts the power of the comparison.
Logistic regression analyses of the relationship between HBoV
detection and disease, after adjustment for patient age, gender and
concurrent HRSV infection, showed that the clinical features
more significantly associated with HBoV were diarrhea (odds ratio
[OR] =37.08; 95% confidence interval [CI]; 3.42–401.98;
p,0.01) and GERD (OR =14.35; 95% CI, 1.03–200.5;
p=0.05). However, neither the rate of hospitalization nor the
presence of LRTI were associated with HBoV detection by logistic
regression (OR =2.14; 95% CI, 0.89–5.19; p=0.09 and OR
=2.15; 95% CI, 0.80–5.73; p=0.13, respectively).
Table 1. Clinical and demographic data of patients with and
without HBoV.
Clinical Data Patients
HBoV + HBoV - Total
Patients 48 (4.8%) 967 (95.2%) 1015 (100.0%)
Masculine gender 32 (66.6%) 504 (52.2%) 536 (52.8%)
Age (median of months) 8.5 8 8
Cough 44 (91.6%) 843 (87.2%) 887 (87.4%)
Coryza 26 (54.1%) 507 (52.4%) 533 (52.5%)
Sneezing 8 (16.6%) 219 (22.6%) 227 (22.3%)
Fever 27 (56.2%) 636 (65.7%) 663 (65.3%)
Wheezing 20 (41.6%) 400 (41.3%) 420 (41.4%)
Dyspnea 27 (56.2%) 464 (47.9%) 491 (48.3%)
Nasal obstruction 15 (31.2%) 360 (37.2%) 375 (36.9%)
Diarrhea* 10 (20.8%) 53 (5.5%) 63 (6.3%)
Requirement for
hospitalization*
40 (83.3%) 653 (67.5%) 693 (68.3%)
Length of hospital stay
(median of days)
99 9
Requirement for O2 23 (47.9%) 403 (41.6%) 426 (41.9%)
Requirement for PAP 2 (4.0%) 70 (7.2%) 72 (7.1%)
ICS =0 7 (14.6%) 219 (22.6%) 226 (22.2%)
ICS =1 6 (12.5%) 144 (14.9%) 150 (14.8%)
ICS =2 9 (18.8%) 179 (18.5%) 188 (18.5%)
ICS =3 6 (12.5%) 132 (13.6%) 138 (13.6%)
ICS =4 13 (27%) 133 (13.8%) 146 (14.4%)
ICS =5 5 (10.4%) 104 (10.8%) 109 (10.8%)
ICS =6 1 (2.1%) 32 (3.3%) 33 (3.3%)
ICS =7 1 (2.1%) 24 (2.5%) 25 (2.4%)
LRTI* 41 (85.4%) 698 (72.2%) 739 (72.8%)
URTI* 7 (14.6%) 269 (27.8%) 276 (27.2%)
AOM 4 (8.3%) 64 (6.6%) 68 (6.7%)
GERD* 4 (8.3%) 41 (4.2%) 45 (4.4%)
PAP=positive airway pressure; ICS=index of clinical severity; LRTI= Lower
respiratory tract infection; URTI= Upper respiratory tract infection; AOM=
Acute otitis media; GERD= Gastro-esophageal reflux disease.* p,0.05.
doi:10.1371/journal.pone.0021083.t001
Marker of Bocavirus Replication in Nasal Secretion
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21083Viral co-infections
All samples positive for HBoV by conventional PCR were tested
for the other respiratory viruses, including HRSV, HRV, HMPV,
FLU, HPIV, HCoV and HAdV. Of 48 HBoV-positive patients, 35
(72.9%) had at least one additional respiratory virus detected (Table
S3). The viruses most frequently detected simultaneously with HBoV
wereHRSVin22(45.8%),HRVin16(33.3%),HMPVin9(18.8%),
and HAdV in 7 (14.5%) patients. The frequencies of co-detection of
one, two, three and four additional viruses in patients with HBoV
were respectively 35.4%, 27.1%, 4.1% and 6.3% (Table S3).
To assess whether this high frequency of co-detection of other
respiratory viruses was a finding specific of HBoV-infected
patients, a subset of 48 samples from HBoV-negative ARI
patients, collected in the same season as those from HBoV-
positive ones, was randomly selected for testing by PCR for the
other respiratory viruses, without knowing the result of the HRSV
or influenza screening for which the samples had been originally
submitted. Such strategy was adopted since it would not be
possible to test all samples for all respiratory viruses. A single
respiratory virus different from HBoV was detected in 26 of 48
(54.1%) patients, and co-detections with more than one agent were
found in an additional 13 (27.1%) (Table S3).
There were no significant differences in frequencies of specific
respiratory symptoms between the patients with ARI in whose
samples only HBoV was detected, and those with HBoV and co-
detection of other viruses. However, significantly lower frequencies
of diarrhea (OR =0.08; 95% CI =0.01–0.40; p,0.01) and
complication of GERD (OR =0.10; 95% CI =0.01–1.05;
p=0.05) were noted in patients with co-detection of other viruses
in addition to HBoV (Table S4).
Quantification of HBoV DNA and detection of HBoV
mRNA
Absolute quantification of DNA by qPCR revealed that the
HBoV viral load in HBoV-positive patients varied very broadly,
over a range that reached 10 decimal orders of magnitude, with
median value of 2.37610
6 copies/mL (Figure 2 and Table S5).
Importantly, the median viral load in samples from patients in
whom HBoV was the only virus detected (1.91610
9 copies/mL),
was significantly higher than that in the patients with HBoV in co-
infection with other respiratory viruses (4.41 6 10
5 copies/mL)
(p,0.001) (Figure 2a).
A comparison of demographics and clinical data between
patients shedding very high HBoV viral loads (.10
8 copies/mL of
NPA) and those shedding lower loads, evidenced significantly
higher frequencies of diarrhea (p,0.01) in patients shedding
higher viral loads (Table 2). Remarkably, detection of other
respiratory viruses simultaneously with HBoV was significantly less
frequent in samples from patients shedding very high loads of
HBoV (p,0.01) (Table 2). Logistic regression analyses confirmed
that diarrhea (OR =6.53; 95% CI =1.41–30.26; p=0.02) were
directly related, whereas simultaneous detection of other viruses in
the NPAs was inversely related (OR =0.01; 95% CI =0.00–0.13;
p,0.01) to the shedding of very high HBoV loads.
The association of shedding very high loads of HBoV
(.10
8 copies/mL) with lack of co-detection of other respiratory
viruses suggested that such high viral loads may result from early
acute HBoV infections with active viral replication, as opposed to
long term shedding unrelated to current clinical symptoms. In
order to confirm this hypothesis, an assay was developed to detect
HBoV VP1 mRNA in NPAs by real time RT-PCR done on total
RNA extracts previously treated with DNAse I. As an internal
control, real time RT-PCR was done for the housekeeping gene of
b-actin. When simultaneously positive for both HBoV VP1 and b-
actin mRNAs, this assay was considered a marker of active HBoV
replication. Positivity for HBoV VP1 or b-actin by PCR done
directly on DNAse-treated material without previous reverse
transcription were considered indicative of remaining genomic
DNA after incomplete DNAse treatment, and samples were
discarded. Of the 48 samples positive for HBoV, 40 had sufficient
remaining volume left for testing. Of those, only 10 (25.0%) tested
positive for VP1 mRNA and, remarkably, 9 of these had very high
HBoV loads of greater than 10
8 copies of DNA/mL. The median
HBoV viral load in patients shedding VP1 mRNA was 8.85 6
10
9 copies/mL, which was significantly higher than that in
patients negative for VP1 HBoV mRNA, 3.82 610
5 copies/mL
(p,0.01) (Figure 2b, Table 3). The association of high viral loads
Figure 1. Monthly distribution of samples positive for HBoV and HRSV in the years 2005 through 2007 in Ribeira ˜o Preto, Brazil in
relation to monthly accumulated rainfall and average temperauture (http://www.ciiagro.sp.gov.br).
doi:10.1371/journal.pone.0021083.g001
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regression (OR =126.0; 95% CI =10.19–999.99; p,0.01).
Importantly, a significant inverse association was noted between
shedding of HBoV VP1 mRNA and having another respiratory
virus detected in the NPA. Four of 10 (40.0%) patients who shed
HBoV VP1 mRNA also had another respiratory virus detected in
their NPAs, whereas 28 of 30 (93%) of the patients in whose
samples shedding of VP1 mRNA was not present, had another
respiratory virus detected in their NPAs (p,0.01) (Table 3). Such
inverse association was confirmed by logistic regression analysis
(OR =0.05; 95% CI =0.01–0.32; p,0.01).
A comparison of clinical features between HBoV patients with
and without shedding of VP1 mRNA revealed an association of
active viral replication with diarrhea (OR =6.00; 95% CI =1.15–
34.14; p=0.04) and a clinical diagnosis of URTI (OR =19.33;
95% CI =1.82–294.96; p=0.01). The frequencies of diarrhea
and diagnosis of URTI in patients shedding VP1 mRNA were
40%, while in patients without detectable VP1 mRNA they were
respectively 10% and 6.6% (Table 3).
Discussion
The results of this cross-sectional study of HBoV in ARI patients
from Ribeira ˜o Preto, Brazil, indicate that shedding of VP1 mRNA
in respiratory secretions, as a marker of HBoV replication,
correlates positively with high viral load, presence of diarrhea, and
lack of co-infection by other respiratory viruses.
During the last five or six years since its discovery, HBoV has
been detected in association with respiratory and gastrointestinal
infections, mostly of children, in many countries in all continents
[2,24]. Rates of detection of HBoV in ARI studies have varied
from 1.5% to 19.0%, depending on patient age, case definition,
and geographic location [2,24]. In the present study, the overall
detection rate of HBoV in ARI patients was 4.8%, similar to rates
in other regions of the world. However, it should be kept in mind
that this study, like most others published on HBoV, was a
hospital-based surveillance, subject to selection bias. Therefore,
rates of HBoV in ARI in the community at large could be
different.
To the best of our knowledge, this has been the largest study of
HBoV in ARI conducted in Brazil and South America. A few
previous studies conducted in the region reported HBoV infection
rates of 6.0% to 10.7% in patients with ARI [9,25,26,27] and in
2.0% of patients with gastroenteritis [15]. Importantly, the present
study revealed a significantly higher rate of concurrent diarrhea in
patients with ARI positive for HBoV as compared to those with
ARI but without detectable HBoV, suggesting a causative role for
HBoV in gastrointestinal manifestations observed in ARI patients.
In general, parvoviruses replicate more efficiently in tissues with
high cellular turnover, such as respiratory and digestive epithelia
[28]. Several members of the family Parvoviridae are known to cause
gastroenteritis, such as canine parvovirus (CPV), feline panleuko-
penia virus (FPV) and canine minute virus (CnMV). In addition
studies previously published by others have reported HBoV
detection in stools from patients with gastroenteritis [29]. Although
the mechanisms of pathogenesis and routes of infection of HBoV
are not yet understood, some information is available for bovine
parvovirus (BPV), another member of the genus Bocavirus. BPV
causes respiratory and enteric diseases in calves following initial
replication in the tonsils and intestinal epithelium, from where it
spreads into the blood, lymphoid tissues and respiratory
epithelium. BPV induces atrophy of microvilli in the small
intestine and death (by apoptosis and necrosis) of lymphoid cells
and ciliated cells of the respiratory epithelium [28].
It is interesting that novel species of HBoV (HBoV 2, 3 and 4)
associated with gastrointestinal infections have recently been
identified [3,4,5] and two of those have been detected in stools
from Brazilian patients with acute diarrhea, at rates varying from
Figure 2. Viral loads of HBoV (copies of genomic DNA/mL) in NPAs by qPCR. A. HBoV viral loads in NPAs from patients with HBoV as single
agent (black circles), and with simultaneous detection of other respiratory viruses (white circles). B. HBoV viral loads in NPAs from patients with (black
circles) and without (white circles) detectable shedding of HBoV VP1 mRNA by real time PCR.
doi:10.1371/journal.pone.0021083.g002
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role for HBoV in human diarrhea still awaits confirmation [30].
Interestingly, in this study a trend was noted for an increase in
respiratory infections, positivity for HRSV and HBoV, in
association with drier and cooler months. While the reasons for
this are not entirely understood, one possibility is that the
increased respiratory virus activity in March and April could be
favored by the initiation of school term one or two months before,
when assembly of susceptible children could provide conditions for
viral spread. The frequency of detection of HBoV in 2005 was
greater than three times that observed in the two following years,
evidence that circulation of this agent in this region of Brazil may
vary greatly from year to year, in a way similar to that previously
documented in Italy [31].
Even though HBoV has been regarded as an infectious agent
present worldwide, its pathogenic role in respiratory illness is still
debatable. This virus is frequently detected in co-infection with
other respiratory viruses of well-established pathogenic role [2,24].
In addition, HBoV is fastidious to propagate in conventional cell
cultures and an experimental infection model is lacking, what
limits advances in understanding pathogenesis. Therefore, the
search for an association of HBoV infections with possible
molecular markers of active viral replication is a useful approache
to investigate pathogenesis of this emerging virus.
In the present study, HBoV DNA was detected by PCR in
samples from ARI patients, but not in nasopharyngeal secretions
collected from asymptomatic children approximately 5 years
before (1999–2000) in the same hospital. The significance of this
finding is limited by the relatively small number of control samples
available for testing, and by the fact that they were collected years
before. However, the lack of detection of HBoV DNA by a
sensitive PCR assay in samples collected from children carefully
scrutinized for the presence of respiratory symptoms, adds support
for a pathogenic role of HBoV in ARI, in agreement with previous
studies [20,32,33].
High frequencies of co-infection by other respiratory viruses in
patients with ARI and HBoV were confirmed in this study with a
rate of 72.9% (35 of 48) of co-infections, mostly caused by HRSV,
Table 2. Clinical and demographic data of ARI patients shedding very high or lower HBoV loads.
Clinical Data Patients
Shedding very high viral loads
# Shedding lower viral loads Total
Patients 17 (35.4%) 31 (64.6%) 48 (100.0%)
Masculine gender 9 (52.9%) 23 (74.2%) 32 (66.6%)
Age (median of months) 10 8 8.5
HBoV viral load (median copies/mL)* 1.0E+09 2.66E+05 2.37E+06
Co-detection of other viruses* 5 (29.4%) 30 (96.8%) 35 (72.9%)
Cough 16 (94.1%) 28 (90.3%) 44 (91.6%)
Coryza 10 (58.8%) 16 (51.6%) 26 (54.1%)
Sneezing 4 (23.5%) 4 (12.9%) 8 (16.6%)
Fever 11 (64.8%) 16 (51.6%) 27 (56.2%)
Wheezing 7 (41.1%) 13 (41.9%) 20 (41.6%)
Dyspnea 8 (47.0%) 19 (61.3%) 27 (56.2%)
Nasal obstruction 4 (23.5%) 11 (35.5%) 15 (31.2%)
Diarrhea* 7 (41.1%) 3 (9.7%) 10 (20.8%)
Requirement for hospitalization 14 (82.3%) 26 (83.8%) 40 (83.3%)
Length of hospital stay (median of days) 8 9 9
Requirement for O2 7 (41.1%) 16 (51.6%) 23 (47.9%)
Requirement for PAP 0 (0.0%) 2 (6.5%) 2 (4.2%)
ICS =0 4 (23.5%) 3 (9.7%) 7 (14.6%)
ICS =1 1 (5.9%) 5 (16.0%) 6 (12.5%)
ICS =2 5 (29.4%) 4 (13.0%) 9 (18.8%)
ICS =3 0 (0.0%) 6 (19.4%) 6 (12.5%)
ICS =4 5 (29.4%) 8 (26.0%) 13 (27.0%)
ICS =5 2 (11.8%) 3 (9.7%) 5 (10.4%)
ICS =6 0 (0.0%) 1 (3.2%) 1 (2.1%)
ICS =7 0 (0.0%) 1 (3.2%) 1 (2.1%)
LRTI 13 (76.4%) 28 (90.3%) 41 (85.4%)
URTI 4 (23.5%) 3 (9.7%) 7 (14.6%)
AOM 1 (5.8%) 3 (9.7%) 4 (8.3%)
GERD 3 (17.6%) 1 (3.2%) 4 (8.3%)
#HBoV viral load .10
8 copies/mL of NPA;
"HBoV viral load ,10
8 copies/mL of NPA; PAP=positive airway pressure; ICS=index of clinical severity; LRTI= Lower
respiratory tract infection; URTI= Upper respiratory tract infection; AOM= Acute otitis media; GERD= Gastro-esophageal reflux disease.* p,0.05
doi:10.1371/journal.pone.0021083.t002
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additional agent. This was similar to the 75% reported by Allander
et al., in Sweden [10], and higher than the 50% reported by
Esposito et al., in Italy [34]. While viral co-infections have long
been recognized in ARI studies, the advent of highly sensitive PCR
assays magnified their observation. In the particular case of
HBoV, frequencies of co-infections have consistently been
reported to be higher than those observed for other respiratory
infections, reaching rates similar to those reported for HAdV [35],
a tendency confirmed by the present study. Yet unproven, this
may suggest that long term shedding of HBoV DNA, unrelated to
current illness may regularly occur, as it is known to happen with
HAdV [36]. Indeed, HBoV DNA was found by PCR in
lymphocytes from palatine tonsils of 32% of children undergoing
tonsillectomy [18], suggesting that this virus can establish latent or
persistent infection in pharyngeal lymphoid tissue.
Another important piece of information befitting a systemic
nature of HBoV infections is the finding of viremia, reported by
Tozer et al. in children with ARI [37]. Viremia was also reported
by Allander et al [10] in HBoV-exclusive infections, a feature
strongly suggestive of a causal role for this agent in acute
symptomatic infections. In addition, those authors reported that
patients with HBoV without concurrent infections by other
respiratory viruses, tended to shed higher HBoV loads [10]. In
this regard, an association of high viral loads in NPAs with HBoV
acute infections, as evidenced by IgM seroconversion in wheezing
children, was clearly documented in a study conducted in Finland
by So ¨derlund-Venermo [38].
These results prompted us to determine HBoV loads by
qPCR in all HBoV-positive NPAs of the study. The results
revealed HBoV viral loads to be significantly higher in patients
without other viral co-infections than in those with multiple
viruses detected. Moreover, rates of diarrhea were significantly
higher in patients with very high HBoV viral loads in their
NPAs. Such finding, in the absence of respiratory viral co-
infections, suggests a causal role for HBoV in the genesis of the
diseases presented by these patients. Nevertheless, detection of a
direct evidence of active replication of HBoV in the secretions
from patients was required to strengthen the causality link
between the virus and disease. In order to do that, an assay to
detect HBoV VP1 mRNA by real time RT-PCR in nasopha-
ryngeal samples was developed. Production of VP1 mRNA is
unequivocal evidence of HBoV replication, but its shedding in
nasopharyngeal secretions does not indicate the possible sources
of virus production. Because RNA is very highly unstable in
ribonuclease-rich respiratory secretions, one can speculate that
VP1 mRNA more likely originates from disruption of sloughed
whole HBoV-infected epithelial cells directly into the RNase-
inhibiting extraction reagent. Unfortunately, preparation of
cytology slides that would have enabled detection of HBoV on
sloughed cells by in situ hybridization was not possible given the
nature of the study.
The presence of extremely high viral loads of HBoV in
secretions, argues in favor of abundant sources of virus, either on
or adjoining the mucosal surfaces. This observation alone
highlights the extremely productive replication levels reached by
HBoV in the permissive upper respiratory tract. However, in situ
studies will be needed to provide definitive localization of viral
replication sites.
To the best of our knowledge this is the first report of an assay
for mRNA to confirm replication of HBoV in clinical samples, and
its application revealed that shedding of VP1 mRNA in
nasopharyngeal secretions was associated with high viral loads,
presence of concurrent diarrhea, and lack of demonstrable co-
infections by other respiratory viruses. Conversely, in the absence
of a marker of current viral replication, HBoV was also often
detected in nasopharyngeal secretions, but in much lower viral
loads and frequently associated with shedding of other pathogenic
respiratory viruses. It should be pointed out that VP1 mRNA was
found only in 25% of the HBoV infected ARI patients, with a
significant part of whom with diarrhea. This may be interpreted to
mean that only one quarter of the HBoV respiratory infections are
associated with genuinely acute viral replication, likely involving
the gastrointestinal tract. Conversely, in most cases of HBoV
detection in respiratory secretions, it may be the result of viral
persistence/latency, with co-detection of another viral agent.
Table 3. Clinical and demographic data of patients shedding
HBoV VP1 mRNA.
Clinical Data Patients
RNAm + RNAm - Total
Patients 10 (25.0%) 30 (75.0%) 40 (100%)
Masculine gender 5 (50.0%) 21 (70%) 26 (65%)
Age (median of months) 9.5 5 8
Patients with high HBoV
load
#*
9 (90.0%) 2 (6.6%) 11 (27.5%)
HBoV viral load (median




4 (40.0%) 28 (93.3%) 32 (80.0%)
Cough 9 (90.0%) 27 (90.0%) 36 (90.0%)
Coryza 6 (60.0%) 17 (56.6%) 23 (57.5%)
Sneezing 1 (10.0%) 5 (16.6%) 6 (15.0%)
Fever 5 (50.0%) 16 (53.3%) 21 (52.5%)
Wheezing 4 (40.0%) 11 (36.6%) 15 (37.5%)
Dyspnea 4 (40.0%) 18 (60.0%) 22 (55.0%)
Nasal obstruction 4 (40.0%) 10 (33.3%) 14 (35.0%)
Diarrhea* 4 (40.0%) 3 (10.0%) 7 (17.5%)
Requirement for
hospitalization
7 (70.0%) 23 (76.6%) 30 (75.0%)
Length of hospital stay
(median of days)
69 9
Requirement for O2 3 (30.0%) 16 (53.3%) 19 (47.5%)
Requirement for PAP 0 (0.0%) 2 (6.6%) 2 (5.0%)
ICS =0 4 (40.0%) 3 (10.0%) 7 (17.5%)
ICS =1 1 (10.0%) 5 (16.6%) 6 (15.0%)
ICS =2 2 (20.0%) 4 (13.4%) 6 (15.0%)
ICS =3 0 (0.0%) 5 (16.6%) 5 (12.5%)
ICS =4 2 (20.0%) 8 (26.8%) 10 (25.0%)
ICS =5 1 (10.0%) 3 (10.0%) 4 (10.0%)
ICS =6 0 (0.0%) 1 (3.3%) 1 (2.5%)
ICS =7 0 (0.0%) 1 (3.3%) 1 (2.5%)
LRTI* 6 (60.0%) 28 (93.3%) 34 (77.5%)
URTI* 4 (40.0%) 2 (6.6%) 6 (15.0%)
AOM 2 (20.0%) 2 (6.6%) 4 (10.0%)
GERD 1 (10.0%) 3 (10.0%) 4 (10.0%)
#HBoV viral load .10
8 copies/mL of NPA, PAP=positive airway pressure;
ICS=index of clinical severity; LRTI= Lower respiratory tract infection; URTI=
Upper respiratory tract infection; AOM= Acute otitis media; GERD= Gastro-
esophageal reflux disease.* p,0.05.
doi:10.1371/journal.pone.0021083.t003
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Patients and sample collection
A retrospective cross-sectional study was carried out with
nasopharyngeal aspirates (NPAs) collected from 1015 patients with
ARI (535 males and 480 females) with 1 month to 66 years of age
(median age of 8 months). The samples were from outpatients and
inpatients brought for health care at the Hospital of the University
of Sa ˜o Paulo School of Medicine, Ribeira ˜o Preto, SP, Brazil, from
January 2005 through December 2007. The study included all
samples from patients with symptoms of ARI seen at any of the
hospital clinics and wards, submitted to the virology laboratory for
testing. The vast majority of the samples had been originally sent
to the laboratory for respiratory syncytial virus and influenza
screening and no exclusion criteria were applied. Clinical
information obtained retrospectively from patient records upon
discharge was entered on study forms. Clinical data collected
included the presence of wheezing, cough, fever, sneezing,
dyspnea, coryza, nasal obstruction, diarrhea, requirement for
oxygen therapy and length of hospitalization. NPAs were collected
in saline solution from all patients [9] and sent on ice to the
virology laboratory within four hours. In addition to the 1015
samples from ARI patients, a convenience set of 50 control
samples from patients without any respiratory symptoms who were
participants in a previous study [23] were used as negative
controls. This group consisted of 26 males, with median age of
19.5 months, mean of 37 months (SD =44 months). After routine
virology sample processing, remaining samples were split into
backup aliquots, including two in Trizol Reagent (Invitrogen
Carlsbad, CA), which were kept in storage at 270uC [9]. This
study was approved by the Internal Review Board of the Hospital
das Clı ´nicas de Ribeira ˜o Preto (HCFMRP-USP) under approval
number 4856/2004. All patients or the parents or guardians of the
patients in the study signed an informed consent form.
Clinical Illness Stratification
Illnesses presented by all patients in this study were classified as
lower respiratory tract infections (LRTI) and upper respiratory
tract infections (URTI), with or without acute otitis media (AOM)
and gastro-esophageal reflux disease (GERD). Patients with URTI
had only symptoms of the upper respiratory tract, such as coryza,
sneezing, nasal obstruction and sore throat, without wheezing, and
dyspnea, with or without fever. Patients with LRTI had diagnosis
of bronchiolitis, bronchiolitis obliterans, bronchodysplasia or
pneumonia. They had wheezing and/or dyspnea, with or without
fever, cough, coryza, sneezing or nasal obstruction. All patients
were assigned to a single clinical definition, and could not be
allocated to more than one group.
In order to assess disease severity, a numeric index of clinical
severity (ICS) was adapted from Walsh et al (1997) [39], based on
the presence of clear-cut criteria that indicate higher risk for severe
disease: wheezing, requirement for hospitalization, oxygen therapy
and positive airway pressure. For all patients the ICS was obtained
by attributing 1 point each for the presence of wheezing,
requirement for hospitalization, length of hospital stay longer
than 5 days, requirement for O2, and use of O2 for longer than 5
days; and 2 extra points attributed in case of requirement for
positive airway pressure, for a maximum ICS equal to 7.
PCR for respiratory viruses
DNA and RNA were extracted from 250 mL of NPA using,
respectively, WizardH Genomic DNA Purification Kit (PromegaH,
Madison, WI, USA) and TrizolH (InvitrogenH, Carlsbad, CA,
USA), following manufacturers protocol.
Detection of HBoV and other respiratory viruses was conducted
by conventional PCR, as previously described [9]. For detection of
HBoV and human adenovirus (HAdV), 100 ng of extracted DNA
was used, whereas for other respiratory viruses, including human
respiratory syncytial virus (HRSV), human metapneumovirus
(HMPV), human rhinovirus (HRV), human influenza virus (FLU),
human parainfluenza viruses (HPIV) and human coronaviruses
(HCoV), PCR was done with cDNA generated by reverse
transcription (RT) of 1 mg of RNA, primed with 10 pmol of
random hexamers, using ImProm-II Reverse Transcriptase
(Promega, Madison, WI) following manufacturer’s instructions.
Prior to reverse transcription, RNA was denatured at 95uC for 5
minutes, then immediately placed on ice while reverse transcrip-
tase was added and then incubated at 42uC for 2 hours. PCR was
done with150 ng of DNA, 10 pmol forward and reverse primers
(Table S1), 50 mM MgCL2,1 0mM deoxynucleoside triphosphate
(dNTP), 2.5 mL of supplied 10 X buffer, 1U of Taq DNA
polymerase (Invitrogen Carlsbad, CA) and water to complete the
volume of 25 mL. The cycling conditions were denaturation at
95uC for 5 min, followed by 35 cycles of 94uC for 1 min, 48uCt o
54uC for 1 min, 72uC for 2 min, and then a final extension step of
72uC for 10 min [9]. All PCR products were analyzed by
electrophoresis in ethidium bromide-stained 1.5% agarose gels.
PCR products of all tested viruses were cloned into the plasmid
pGEM-T easy (Promega, Madison, Wisconsin) and used to
determine detection limits for each assay. All clones were
sequenced with BigDye Terminator v3.1 Cycle Sequencing
(Applied Biosystems, Foster City, CA) using the ABI Prism 3100
Genetic Analyzer. The detection limits for the PCR assays were
determined by testing serial decimal dilutions of the clones, and
results varied from 1 to 100 copies of plasmid DNA. The limit of
detection for HBoV was determined to be 40 copies. All applicable
measures to prevent contamination of PCR reactions were taken
in this study.
Quantitative real-time PCR for HBoV
The quantitative PCR (qPCR) for HBoV was targeted to the
viral NP1 gene according to previously published procedures [40].
Briefly, the reaction was performed in triplicate in a final volume
of 10 mL, containing 150 ng of template DNA, 5 mL of TaqMan
universal PCR master mix (Applied Biosystems Foster City, CA),
300 nmol/L of each primer and 150 nmol/L of probe (Table S1).
The amplification was performed on a 7300 Real Time PCR
system (Applied Biosystems Foster City, CA) with the following
settings: 50uC for 10 min, 95uC for 3 min and 45 cycles of 95uC
for 15 s and 60uC for 1 min. A standard curve of amplification
was produced using serial decimal dilutions of a plasmid (pGEM-
FULL4HBoV) in which a fragment of the HBoV NP1 gene
(2270 nt to 3280 nt) was cloned. A positive qPCR for HBoV was
considered when the threshold was reached before the 40
th cycle
with fluorescence count higher than 0.5. The detection limit was
4.6 copies of HBoV plasmid, the slope and the R2 of the standard
curve were 23,386 and 0,994, respectively. All qPCR results were
normalized by the amplification of the b-actin gene, included in
duplicate in all tested batches, using 300 nmol/L of each primer
and 150 nmol/L of the probe (Table S1). With this approach, viral
loads were determined as the number of copies of HBoV DNA per
mL of NPAs.
Real-time RT-PCR for the VP1 mRNA of HBoV
Shedding of HBoV VP1 mRNA was tested by real-time RT-
PCR in NPAs to ascertain the presence of active viral replication,
as opposed to shedding of viral genome. To ensure target-specific
amplification total RNA extraction products were treated with
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control, the same PCR was done in parallel directly with the RNA
extraction product without previous RT. Samples were considered
positive for HBoV VP1 mRNA only when they were simulta-
neously negative for amplification directly from the extracted
RNA without previous RT. RT was performed on 1 mg of RNA
extracted by Trizol using10 pmol of random primers, according to
the protocol provided by the manufacturer. After RNA denatur-
ation at 95uC for 5 min reverse transcriptase was added and
incubation went on for 2 h at 42uC. PCR was then carried out
with 150 ng of cDNA, with 300 nmol/L of each primer (VP1-F
and VP2-R), 150 nmol/L of the probe (VP1-S, Table S1), and
5 mL of TaqMan universal PCR master mix (Applied Biosystems
Foster City, CA). Amplification was done using the 7300 Real
Time PCR system (Applied Biosystems Foster City, CA) with the
following settings: 50uC for 10 min, 95uC for 3 min and 45cycles
of 95uC for 15 s and 60uC for 1 m. All samples, including all
cDNAs and RNAs pre-treated with DNAse, were tested by qPCR
for b-actin mRNA, following the protocol described above.
Samples found to be positive for b-actin by amplification directly
from the RNA not pre-treated with DNase, were considered to be
false positives. As above mentioned, positive reactions were
considered when the threshold was reached before the 40
th cycle,
with a fluorescence higher than 0.5. The detection limit of this
assay was found to be 3 copies of DNA, as determined using the
decimal serial dilutions of viral cDNA obtained from in vitro
transcription of a plasmid containing theVP1 gene, according to
manufactures’ instructions (Riboprobe in vitro transcription
systems, Promega Madison, WI).
Statistical Analysis
Correlation between positivity for HBoV and clinical conditions
was assessed by the Chi-square test. Statistical analysis was
conducted using the BioEstat 3.0 software (CNPq, Brazil). Logistic
regression was done to examine the relationship of HBoV
shedding (including positivity for HBoV DNA, HBoV loads, lack
of other viral co-infections and detection of HBoV VP1 mRNA)
and clinical data adjusted for age, gender and detection of HRSV
in the same samples [41]. To analyze the HBoV loads obtained by
qPCR, data in two unpaired groups of patients were compared
with the Mann-Whitney test. These analyses were performed using
the SASH 9.0software (SAS Institute Inc, Raleigh, NC). A p value
of #0.05 was chosen for significance.
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